fda glp-1 safety alert october 2025 US removes suicidal thoughts warning from weight-loss drugs Semaglutide Safety Alerts, Recalls &

GLP-1 and pregnancy or lactation are not recommended

At 68 weeks, treatment was stopped but a small group continued taking semaglutide for a year as part of an extension trial

They are intentionally overfilled so you can withdraw the full labeled dose without worrying about air bubbles or dead space in the syringe

Rexhaj, E

For those seeking more modest amounts of weight loss, any of the currently available medications are likely to work and the choice can be driven by a variety of factors: insurance coverage, availability, formulation (injection vs oral), and ease of access and use

Convenient form: Spray guarantees high bioavailability and ease of application